KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $245.5 million.

  • Emergent BioSolutions' Cash & Equivalents rose 63.78% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 63.78%. This contributed to the annual value of $99.5 million for FY2024, which is 10.92% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Cash & Equivalents is $245.5 million, which was down 8.16% from $267.3 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Cash & Equivalents high stood at $642.6 million for Q4 2022, and its period low was $69.7 million during Q2 2024.
  • Over the past 3 years, Emergent BioSolutions' median Cash & Equivalents value was $111.7 million (recorded in 2023), while the average stood at $161.6 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Cash & Equivalents plummeted by 82.62% in 2023, and later skyrocketed by 283.50% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Cash & Equivalents (Quarterly) stood at $576.1 million in 2021, then grew by 11.54% to $642.6 million in 2022, then tumbled by 82.62% to $111.7 million in 2023, then dropped by 10.92% to $99.5 million in 2024, then spiked by 63.78% to $245.5 million in 2025.
  • Its Cash & Equivalents was $245.5 million in Q3 2025, compared to $267.3 million in Q2 2025 and $149.1 million in Q1 2025.